Kalytera Announces Management Changes and Expansion of Leadership Team
June 22, 2017 07:00 ET
|
Kalytera Therapeutics, Inc.
SAN FRANCISCO and TEL AVIV, Israel, June 22, 2017 (GLOBE NEWSWIRE) -- Kalytera Therapeutics, Inc. (TSXV:KALY) (OTCQB:KALTF), a clinical-stage pharmaceutical company developing cannabinoid...
Kalytera Reports First Quarter 2017 Financial Results
May 31, 2017 07:00 ET
|
Kalytera Therapeutics, Inc.
VANCOUVER, British Columbia, May 31, 2017 (GLOBE NEWSWIRE) -- Kalytera Therapeutics, Inc. (TSX-V:KALY) (OTCQB:KALTF), a clinical-stage pharmaceutical company developing cannabinoid therapeutics for...
Kalytera Announces Changes to its Board of Directors
May 26, 2017 07:30 ET
|
Kalytera Therapeutics, Inc.
VANCOUVER, British Columbia, May 26, 2017 (GLOBE NEWSWIRE) -- Kalytera Therapeutics, Inc. (TSXV:KALY) (OTCQB:KALTF), a clinical-stage pharmaceutical company developing cannabinoid therapeutics for...
Kalytera Reports FY 2016 Results; Provides Corporate Update and 2017 Outlook
May 02, 2017 08:30 ET
|
Kalytera Therapeutics, Inc.
VANCOUVER, British Columbia, May 02, 2017 (GLOBE NEWSWIRE) -- Kalytera Therapeutics, Inc. (TSXV:KALY) (OTCQB:KALTF), a clinical-stage biopharmaceutical company developing cannabinoid-derived...
Kalytera Identifies Sites for Planned GvHD Clinical Trials; Company’s Research Gains Support at EBMT 2017
April 25, 2017 08:30 ET
|
Kalytera Therapeutics, Inc.
VANCOUVER, British Columbia, April 25, 2017 (GLOBE NEWSWIRE) -- Kalytera Therapeutics, Inc. (TSXV:KALY), a clinical-stage biopharmaceutical company developing next-generation cannabinoid-derived...
Kalytera Applies for $5 Million R&D Grant from IIA
April 17, 2017 08:30 ET
|
Kalytera Therapeutics, Inc.
VANCOUVER, British Columbia, April 17, 2017 (GLOBE NEWSWIRE) -- Kalytera Therapeutics, Inc. (TSXV:KALY), a clinical stage biopharmaceutical company developing next generation cannabinoid-derived...
Kalytera Therapeutics Appoints Pini Ben-Elazar to Board of Directors
March 17, 2017 08:30 ET
|
Kalytera Therapeutics, Inc.
VANCOUVER, British Columbia, March 17, 2017 (GLOBE NEWSWIRE) -- Kalytera Therapeutics, Inc. (TSXV:KALY) today announced that Mr. Pini Ben-Elazar has been appointed to Kalytera’s Board of Directors. ...
Kalytera Therapeutics Announces Encouraging Results of a Phase 2a Clinical Study for the Treatment of Acute Graft versus Host Disease
February 22, 2017 09:18 ET
|
Kalytera Therapeutics, Inc.
VANCOUVER, British Columbia, Feb. 22, 2017 (GLOBE NEWSWIRE) -- Kalytera Therapeutics, Inc. (TSXV:KALY) (“Kalytera”) is pleased to announce encouraging results from a Phase 2a study evaluating the...
Kalytera Therapeutics to Announce Phase 2a Clinical Study Results Investigating CBD for the Treatment of Acute Graft versus Host Disease
February 16, 2017 16:30 ET
|
Kalytera Therapeutics, Inc.
VANCOUVER, British Columbia, Feb. 16, 2017 (GLOBE NEWSWIRE) -- Kalytera Therapeutics, Inc. (TSXV:KALY) (“Kalytera”) will announce the results of a Phase 2a study investigating the safety and...
Kalytera Therapeutics Completes Acquisition of Talent Biotechs
February 16, 2017 08:30 ET
|
Kalytera Therapeutics, Inc.
Lead program in Graft versus Host Disease (“GvHD”), a life-threatening condition that can occur following stem cell or bone marrow transplantationFour Phase 2 clinical studies evaluating CBD in the...